531739 — Gennex Laboratories Share Price
- IN₹3.70bn
- IN₹3.69bn
- IN₹656.03m
- 44
- 19
- 79
- 44
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.27 | ||
Price to Tang. Book | 4.59 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 5.14 | ||
EV to EBITDA | 26.04 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 10.67% | ||
Return on Equity | 15.28% | ||
Operating Margin | 16.22% |
Financial Summary
Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 558.03 | 556.17 | 596.49 | 612.14 | 656.03 | n/a | n/a | 8.43% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +167.54 | -19.97 | +143.88 | -9.48 | +13.86 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The Company has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company operates through the Pharmaceutical Products (Bulk Drugs) segment. The Company's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The Company has manufacturing facilities in India which cater to both domestic and international markets.
Directors
- K. Bhaswanth COO
- Rajesh Vankadara, CCO
- Arihant Baid MDR
- Tiruvarur Gopalakrishnan EDR
- U. Bhandari NID (60)
- Y. Ravinder Reddy NID (47)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 29th, 1990
- Public Since
- February 9th, 1996
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 227,447,674
- Address
- Akash Ganga 3rd Floor, HYDERABAD, 500073
- Web
- https://www.gennexlab.com/
- Phone
- +91 4067334400
- Auditors
- PPKG & Co
Upcoming Events for 531739
Q1 2025 Gennex Laboratories Ltd Earnings Release
Similar to 531739
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
Ambalal Sarabhai Enterprises
Bombay Stock Exchange
FAQ
As of Today at 19:09 UTC, shares in Gennex Laboratories are trading at IN₹16.25. This share price information is delayed by 15 minutes.
Shares in Gennex Laboratories last closed at IN₹16.25 and the price had moved by +165.52% over the past 365 days. In terms of relative price strength the Gennex Laboratories share price has outperformed the S&P BSE 100 Index by +101.24% over the past year.
There is no consensus recommendation for this security.
Gennex Laboratories does not currently pay a dividend.
Gennex Laboratories does not currently pay a dividend.
Gennex Laboratories does not currently pay a dividend.
To buy shares in Gennex Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹16.25, shares in Gennex Laboratories had a market capitalisation of IN₹3.70bn.
Here are the trading details for Gennex Laboratories:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 531739
Based on an overall assessment of its quality, value and momentum Gennex Laboratories is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gennex Laboratories. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +9.64%.
As of the last closing price of IN₹16.25, shares in Gennex Laboratories were trading +21.3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Gennex Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹16.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Gennex Laboratories' management team is headed by:
- K. Bhaswanth - COO
- Rajesh Vankadara, - CCO
- Arihant Baid - MDR
- Tiruvarur Gopalakrishnan - EDR
- U. Bhandari - NID
- Y. Ravinder Reddy - NID